Acute kidney injury from SGLT2 inhibitors: potential mechanisms

SGLT2 inhibitors have shown great promise in the management of diabetes mellitus and the prevention of cardiovascular complications, but increasing evidence suggests that their use can be associated with an increased risk of acute kidney injury. Insights into the mechanisms involved might help to identify individuals who are at risk of renal injury.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Proposed mechanisms of renal injury from SGLT2 inhibitors.

References

  1. 1

    Skrtic, M. et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57, 2599–2602 (2014).

    Article  PubMed  Google Scholar 

  2. 2

    Zinman, B., Lachin, J. M. & Inzucchi, S. E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2016).

    Article  Google Scholar 

  3. 3

    Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Hahn, K., Kanbay, M., Lanaspa, M. A., Johnson, R. J. & Ejaz, A. A. Serum uric acid and acute kidney injury: a mini review. J. Advanced Research (in press).

  5. 5

    Bjornstad, P. et al. Fructose and uric acid in diabetic nephropathy. Diabetologia 58, 1993–2002 (2015).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Kitamura, H. et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int. 53, 146–153 (1998).

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported by NIH grants DK109408-01A1 (to R.J.J.) and DK108859-01 (to M.A.L.)

Author information

Affiliations

Authors

Corresponding author

Correspondence to Richard J. Johnson.

Ethics declarations

Competing interests

R.J.J. and M.A.L. have patents and patent applications related to blocking fructose metabolism, and are members of Colorado Research Partners, which is a startup company that is attempting to make inhibitors of fructose metabolism. R.J.J. is also on the Scientific Board of XORT Therapeutics and Amway. The other authors declare no competing interests.

PowerPoint slides

Related links

Related links

FURTHER INFORMATION

FDA Drug Safety Communication. 14 June 2016

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hahn, K., Ejaz, A., Kanbay, M. et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12, 711–712 (2016). https://doi.org/10.1038/nrneph.2016.159

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing